Cargando…

SARS-CoV-2 antibody prevalence, titres and neutralising activity in an antenatal cohort, United Kingdom, 14 April to 15 June 2020

SARS-CoV-2 IgG screening of 1,000 antenatal serum samples in the Oxford area, United Kingdom, between 14 April and 15 June 2020, yielded a 5.3% seroprevalence, mirroring contemporaneous regional data. Among the 53 positive samples, 39 showed in vitro neutralisation activity, correlating with IgG tit...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lumley, Sheila F, Eyre, David W, McNaughton, Anna L, Howarth, Alison, Hoosdally, Sarah, Hatch, Stephanie B, Kavanagh, James, Chau, Kevin K, Downs, Louise O, Cox, Stuart, Dunn, Laura, Justice, Anita, Wareing, Susan, Dingle, Kate, Rudkin, Justine, Auckland, Kathryn, Fyfe, Alexander, Bolton, Jai, Paton, Robert, Mentzer, Alexander J, Jeffery, Katie, Andersson, Monique I, James, Tim, Peto, Tim E A, Marsden, Brian D, Screaton, Gavin, Cornall, Richard J, Klenerman, Paul, Ebner, Daniel, Stuart, David I, Crook, Derrick W, Stoesser, Nicole, Kennedy, Stephen H, Thompson, Craig, Gupta, Sunetra, Matthews, Philippa C
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	European Centre for Disease Prevention and Control (ECDC) 2020
Materias:	Rapid Communication
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7651878/ https://www.ncbi.nlm.nih.gov/pubmed/33094717 http://dx.doi.org/10.2807/1560-7917.ES.2020.25.41.2001721

Ejemplares similares

SARS-CoV-2 RNA detected in blood products from patients with COVID-19 is not associated with infectious virus
por: Andersson, Monique I., et al.
Publicado: (2020)

Stringent thresholds in SARS-CoV-2 IgG assays lead to under-detection of mild infections
por: Eyre, David W., et al.
Publicado: (2021)

The Duration, Dynamics, and Determinants of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Antibody Responses in Individual Healthcare Workers
por: Lumley, Sheila F, et al.
Publicado: (2021)

Neutralising antibody titres as predictors of protection against SARS-CoV-2 variants
por: Pallett, Scott J C, et al.
Publicado: (2022)

Antibody Status and Incidence of SARS-CoV-2 Infection in Health Care Workers
por: Lumley, Sheila F., et al.
Publicado: (2020)

Quantitative SARS-CoV-2 anti-spike responses to Pfizer–BioNTech and Oxford–AstraZeneca vaccines by previous infection status
por: Eyre, David W., et al.
Publicado: (2021)

SARS-CoV-2 neutralising antibody testing in Europe: towards harmonisation of neutralising antibody titres for better use of convalescent plasma and comparability of trial data
por: Nguyen, Dung, et al.
Publicado: (2021)

Neutralising antibody titres as predictors of protection against SARS-CoV-2 variants and the impact of boosting: a meta-analysis
por: Cromer, Deborah, et al.
Publicado: (2022)

Neutralisation titres against SARS-CoV-2 are sustained 6 months after onset of symptoms in individuals with mild COVID-19
por: Underwood, Alexander P., et al.
Publicado: (2021)

Neutralising activity and antibody titre in 10 patients with breakthrough infections of the SARS-CoV-2 Omicron variant in Japan
por: Okumura, Nobumasa, et al.
Publicado: (2022)

Reduced neutralisation of SARS-CoV-2 omicron B.1.1.529 variant by post-immunisation serum
por: Dejnirattisai, Wanwisa, et al.
Publicado: (2022)

Sero-Monitoring of Horses Demonstrates the Equivac(®) HeV Hendra Virus Vaccine to Be Highly Effective in Inducing Neutralising Antibody Titres
por: Halpin, Kim, et al.
Publicado: (2021)

An Observational Cohort Study on the Incidence of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection and B.1.1.7 Variant Infection in Healthcare Workers by Antibody and Vaccination Status
por: Lumley, Sheila F, et al.
Publicado: (2021)

Convalescent plasma therapy for the treatment of patients with COVID‐19: Assessment of methods available for antibody detection and their correlation with neutralising antibody levels
por: Harvala, Heli, et al.
Publicado: (2020)

Differential occupational risks to healthcare workers from SARS-CoV-2 observed during a prospective observational study
por: Eyre, David W, et al.
Publicado: (2020)

Induction of high titred, non-neutralising antibodies by self-adjuvanting peptide epitopes derived from the respiratory syncytial virus fusion protein
por: Jaberolansar, Noushin, et al.
Publicado: (2017)

Epidemiological data and genome sequencing reveals that nosocomial transmission of SARS-CoV-2 is underestimated and mostly mediated by a small number of highly infectious individuals
por: Lumley, Sheila F, et al.
Publicado: (2021)

Protection against SARS-CoV-2 Omicron BA.4/5 variant following booster vaccination or breakthrough infection in the UK
por: Wei, Jia, et al.
Publicado: (2023)

Mortality risks associated with empirical antibiotic activity in Escherichia coli bacteraemia: an analysis of electronic health records
por: Yoon, Chang Ho, et al.
Publicado: (2022)

Temporally separated feline calicivirus isolates do not cluster phylogenetically and are similarly neutralised by high-titre vaccine strain FCV-F9 antisera in vitro
por: Smith, Shirley L, et al.
Publicado: (2019)

Evaluation of sequence hybridization for respiratory viruses using the Twist Bioscience Respiratory Virus Research panel and the OneCodex Respiratory Virus sequence analysis workflow
por: Kapel, Natalia, et al.
Publicado: (2023)

SARS-CoV-2 antibody trajectories after a single COVID-19 vaccination with and without prior infection
por: Wei, Jia, et al.
Publicado: (2022)

Antibody responses and correlates of protection in the general population after two doses of the ChAdOx1 or BNT162b2 vaccines
por: Wei, Jia, et al.
Publicado: (2022)

Anti-spike antibody response to natural SARS-CoV-2 infection in the general population
por: Wei, Jia, et al.
Publicado: (2021)

Antibody responses to SARS-CoV-2 vaccines in 45,965 adults from the general population of the United Kingdom
por: Wei, Jia, et al.
Publicado: (2021)

Estimated protection against COVID-19 based on predicted neutralisation titres from multiple antibody measurements in a longitudinal cohort, France, April 2020 to November 2021
por: Woudenberg, Tom, et al.
Publicado: (2023)

Genomic diversity affects the accuracy of bacterial single-nucleotide polymorphism–calling pipelines
por: Bush, Stephen J, et al.
Publicado: (2020)

High precision Neisseria gonorrhoeae variant and antimicrobial resistance calling from metagenomic Nanopore sequencing
por: Sanderson, Nicholas D., et al.
Publicado: (2020)

Identification of neutralising pembrolizumab anti-drug antibodies in patients with melanoma
por: Sasson, S. C., et al.
Publicado: (2021)

A novel near-patient host-protein score predicts COVID-19 deterioration at presentation to secondary care
por: Shah, Rahul Atul, et al.
Publicado: (2023)

Clostridium difficile trehalose metabolism variants are common and not associated with adverse patient outcomes when variably present in the same lineage
por: Eyre, David W., et al.
Publicado: (2019)

Neutralisation and the brickwall
por: Hereward, H G
Publicado: (1974)

SARS-CoV-2 seroprevalence, and IgG concentration and pseudovirus neutralising antibody titres after infection, compared by HIV status: a matched case-control observational study
por: Spinelli, Matthew A, et al.
Publicado: (2021)

Hash-Based Core Genome Multilocus Sequence Typing for Clostridium difficile
por: Eyre, David W., et al.
Publicado: (2019)

Virus Neutralisation: New Insights from Kinetic Neutralisation Curves
por: Magnus, Carsten
Publicado: (2013)

Titres StockShots: Video History
Publicado: (2016)

BugMat and FindNeighbour: command line and server applications for investigating bacterial relatedness
por: Mazariegos-Canellas, Oriol, et al.
Publicado: (2017)

Evolutionary History of the Clostridium difficile Pathogenicity Locus
por: Dingle, Kate E., et al.
Publicado: (2013)

Two Distinct Patterns of Clostridium difficile Diversity Across Europe Indicating Contrasting Routes of Spread
por: Eyre, David W, et al.
Publicado: (2018)

Clinical Clostridium difficile: Clonality and Pathogenicity Locus Diversity
por: Dingle, Kate E., et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_8esejmofact4ubugj9cab9bc8t